A I Green

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi request reprint First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol
    Alan I Green
    Commonwealth Research Center and the Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
    Schizophr Res 66:125-35. 2004
  2. ncbi request reprint Olanzapine and haloperidol in first episode psychosis: two-year data
    A I Green
    Department of Psychiatry, Dartmouth Medical School, DHMC, Lebanon, NH 03756, USA
    Schizophr Res 86:234-43. 2006
  3. ncbi request reprint Schizophrenia and comorbid substance use disorder: effects of antipsychotics
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Clin Psychiatry 66:21-6. 2005
  4. ncbi request reprint Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Hanover, NH 03756, USA
    J Clin Psychiatry 67:31-5; quiz 36-7. 2006
  5. pmc Substance abuse and schizophrenia: pharmacotherapeutic intervention
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Subst Abuse Treat 34:61-71. 2008
  6. ncbi request reprint Pharmacotherapy for schizophrenia and co-occurring substance use disorders
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School DHMC, One Medical Center Drive, Lebanon, NH 03756 0001, USA
    Neurotox Res 11:33-40. 2007
  7. ncbi request reprint Clozapine reduces alcohol drinking in Syrian golden hamsters
    Alan I Green
    Commonwealth Research Center, Massachusetts Mental Health Center, 74 Fenwood Road, Boston 02115, USA
    Psychiatry Res 128:9-20. 2004
  8. ncbi request reprint The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
    R E Drake
    New Hampshire Dartmouth Psychiatric Research Center, Dartmouth Medical School, Lebanon, NH, USA
    Schizophr Bull 26:441-9. 2000
  9. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
  10. ncbi request reprint Schizophrenia and co-occurring substance use disorder
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA
    Am J Psychiatry 164:402-8. 2007

Detail Information

Publications42

  1. ncbi request reprint First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol
    Alan I Green
    Commonwealth Research Center and the Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
    Schizophr Res 66:125-35. 2004
    ..We report on rates of co-occurring substance use disorders in patients within their first episode of schizophrenia-related psychosis from a multicenter, international treatment trial of olanzapine vs. haloperidol...
  2. ncbi request reprint Olanzapine and haloperidol in first episode psychosis: two-year data
    A I Green
    Department of Psychiatry, Dartmouth Medical School, DHMC, Lebanon, NH 03756, USA
    Schizophr Res 86:234-43. 2006
    ..The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine...
  3. ncbi request reprint Schizophrenia and comorbid substance use disorder: effects of antipsychotics
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Clin Psychiatry 66:21-6. 2005
    ..Further research is required, but early evidence suggests that at least some atypical antipsychotics may prove to be therapeutically effective in the treatment of patients with schizophrenia and comorbid substance use disorder...
  4. ncbi request reprint Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Hanover, NH 03756, USA
    J Clin Psychiatry 67:31-5; quiz 36-7. 2006
    ..The adjunctive use of naltrexone or other agents also may be helpful. Further research on the optimal pharmacologic approach to patients with dual diagnosis is needed...
  5. pmc Substance abuse and schizophrenia: pharmacotherapeutic intervention
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Subst Abuse Treat 34:61-71. 2008
    ..Further studies are required to establish a solid evidence base of best practices for the use of medications in these patients...
  6. ncbi request reprint Pharmacotherapy for schizophrenia and co-occurring substance use disorders
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School DHMC, One Medical Center Drive, Lebanon, NH 03756 0001, USA
    Neurotox Res 11:33-40. 2007
    ..Ultimately, any medication given to these patients will need to be prescribed within psychosocial treatment programs aimed at assisting these patients in limiting and ultimately ceasing substance use...
  7. ncbi request reprint Clozapine reduces alcohol drinking in Syrian golden hamsters
    Alan I Green
    Commonwealth Research Center, Massachusetts Mental Health Center, 74 Fenwood Road, Boston 02115, USA
    Psychiatry Res 128:9-20. 2004
    ..These data further suggest that clozapine may serve as a prototype for developing novel treatments for alcohol abuse...
  8. ncbi request reprint The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
    R E Drake
    New Hampshire Dartmouth Psychiatric Research Center, Dartmouth Medical School, Lebanon, NH, USA
    Schizophr Bull 26:441-9. 2000
    ..The use of clozapine by patients with co-occurring substance disorders deserves further study in randomized clinical trials...
  9. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
    ..Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects...
  10. ncbi request reprint Schizophrenia and co-occurring substance use disorder
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA
    Am J Psychiatry 164:402-8. 2007
  11. ncbi request reprint Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
    ..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
  12. ncbi request reprint Glucose effects on cognition in schizophrenia
    William S Stone
    Department of Psychiatry at Massachusetts Mental Health Center MMHC, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
    Schizophr Res 62:93-103. 2003
    ..They also highlight the need to explore the extent to which glucose modulates nonmemory cognitive functions such as attention, and to understand more generally how glucose availability and regulation influence cognition...
  13. pmc Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders
    Mary F Brunette
    Department of Psychiatry, Dartmouth Medical School, New Hampshire Dartmouth Psychiatric Research Center, Concord, NH 03301, USA
    Schizophr Bull 32:637-43. 2006
    ..This research, however, could be biased by selection factors. Studying patients who are currently in substance abuse remission could control for level of motivation to stop using substances and other methodological confounds...
  14. ncbi request reprint The history of community mental health treatment and rehabilitation for persons with severe mental illness
    Robert E Drake
    Dartmouth Medical School, Lebanon, NH, USA
    Community Ment Health J 39:427-40. 2003
    ..Current treatments are based on a much stronger evidence base, are more patient-centered, and are more likely to target autonomy and recovery...
  15. pmc Enhancing validity in co-occurring disorders treatment research
    Gregory J McHugo
    Dartmouth Psychiatric Research Center, 2 Whipple Place, Suite 202, Lebanon, NH 03766, USA
    Schizophr Bull 32:655-65. 2006
    ..The central recommendation is to move rapidly from efficacy studies to more credible and valid effectiveness studies, in order to facilitate the adoption of evidence-based interventions in routine practice settings...
  16. doi request reprint Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters
    David T Chau
    Department of Psychiatry, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA
    Neuropharmacology 58:351-6. 2010
    ....
  17. pmc Current research on co-occurring substance-use disorder in schizophrenia
    Robert E Drake
    Psychiatric Research Center, Department of Psychiatry, Dartmouth Medical School, 2 Whipple Place, Lebanon, NH 03766, USA
    Schizophr Bull 32:616-7. 2006
  18. ncbi request reprint Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:4-46. 2009
    ..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
  19. ncbi request reprint Concurrent validation of schizotaxia: a pilot study
    W S Stone
    Department of Psychiatry at Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
    Biol Psychiatry 50:434-40. 2001
    ....
  20. ncbi request reprint Clozapine in the treatment of refractory psychotic mania
    A I Green
    Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA 02115, USA
    Am J Psychiatry 157:982-6. 2000
    ..The efficacy of clozapine was examined in a group of patients with treatment-refractory bipolar disorder, manic type with psychotic features...
  21. ncbi request reprint Comorbid schizophrenia and substance abuse
    Alan I Green
    Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA
    J Clin Psychiatry 67:e08. 2006
    ..The efficacy of possible treatments for comorbid schizophrenia and substance abuse are weighed, including typical and atypical antipsychotics and psychosocial interventions, and a list of possible adjunctive agents is provided...
  22. ncbi request reprint Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder
    Carla M Canuso
    Commonwealth Research Center, Boston, MA 02115, USA
    Psychiatry Res 111:11-20. 2002
    ....
  23. ncbi request reprint Treatment of schizophrenia and comorbid substance use disorder
    Alan I Green
    Commonwealth Research Center, Harvard Medical School Department of Psychiatry, Boston, MA, USA
    Curr Drug Targets CNS Neurol Disord 1:129-39. 2002
    ..Studies of other agents, employed in the pharmacotherapy of alcohol and substance use disorders without schizophrenia, are currently underway in patients with schizophrenia and comorbid disorders...
  24. ncbi request reprint Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone
    Alan I Green
    Commonwealth Research Center, Boston, MA, USA
    Schizophr Res 60:81-5. 2003
    ....
  25. ncbi request reprint Pharmacotherapy for schizophrenia and co-occurring substance use disorders
    Douglas L Noordsy
    Department of Psychiatry, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA
    Curr Psychiatry Rep 5:340-6. 2003
    ....
  26. ncbi request reprint Detection and management of comorbidity in patients with schizophrenia
    Alan I Green
    Department of Psychiatry, Harvard Medical School, Commonwealth Research Center, Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA
    Psychiatr Clin North Am 26:115-39. 2003
    ....
  27. doi request reprint Clozapine-induced myocarditis: role of catecholamines in a murine model
    Ju Feng Wang
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Eur J Pharmacol 592:123-7. 2008
    ..Our data suggest that a beta-adrenergic blocking agent may be effective in reducing the incidence and severity of clozapine-induced myocarditis...
  28. ncbi request reprint Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo
    Igor Elman
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuropsychopharmacology 27:293-300. 2002
    ..Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect...
  29. ncbi request reprint Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?
    Robert M Roth
    Department of Psychiatry, Dartmouth Medical School DHMC, Lebanon, NH 03756, USA
    Curr Psychiatry Rep 7:283-91. 2005
    ..We propose that effective treatments may in part work through the modulation of brain reward circuitry dysfunction...
  30. doi request reprint Deep brain stimulation of the nucleus accumbens reduces alcohol intake in alcohol-preferring rats
    Michael B Henderson
    Department of Neurosurgery, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Neurosurg Focus 29:E12. 2010
    ....
  31. doi request reprint Comorbid psychiatric and substance abuse disorders: recent treatment research
    Paula Riggs
    Department of Psychiatry, University of Colorado Health Science Cneter, Denver, CO 80224, USA
    Subst Abus 29:51-63. 2008
    ..Treatment of ADHD and substance use disorders in adults; 3. Effects of substance abuse on the onset, severity, and treatment of schizophrenia. Recommendations for further research will be presented...
  32. ncbi request reprint The neural circuitry of reward and its relevance to psychiatric disorders
    David T Chau
    Department of Psychiatry, Dartmouth Medical School, Dartmouth Health and Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Curr Psychiatry Rep 6:391-9. 2004
    ....
  33. ncbi request reprint Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia
    Igor Elman
    Department of Psychiatry, McLean Hospital and Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 176:369-75. 2004
    ..Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function...
  34. ncbi request reprint Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode
    Stephen M Strakowski
    Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0583, Cincinnati, OH 45267 0583, USA
    Schizophr Res 78:161-9. 2005
    ..This improvement is particularly relevant early in the course of schizophrenia...
  35. ncbi request reprint Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
    Arch Gen Psychiatry 60:82-91. 2003
    ..Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients...
  36. ncbi request reprint Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity
    Charlene E Le Fauve
    Division of Clinical and Prevention Research, Treatment Research Branch, NIAAA, Bethesda, Maryland, USA
    Alcohol Clin Exp Res 28:302-12. 2004
    ..The panel focused on social anxiety disorder, depression, bipolar disorder, and schizophrenia...
  37. ncbi request reprint The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
    ..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
  38. ncbi request reprint Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
    ..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
  39. ncbi request reprint Clozapine action on auditory P3 response in schizophrenia
    Margaret A Niznikiewicz
    Schizophr Res 76:119-21. 2005
  40. pmc Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations
    Douglas M Ziedonis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 675 Hoes Lane, Rm D 349, Piscataway, NJ 08854, USA
    J Psychiatr Pract 11:315-39. 2005
    ..An algorithm summarizing the consensus recommendations is provided in an appendix...
  41. ncbi request reprint Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    Robert B Zipursky
    Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Br J Psychiatry 187:537-43. 2005
    ..Substantial weight gain is common with many atypical antipsychotics...
  42. ncbi request reprint Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Eduardo Dunayevich
    Outcomes Research, Eli Lilly and Co, Indianapolis, IN, USA
    J Clin Psychiatry 68:1163-71. 2007
    ..This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes...

Research Grants16

  1. ALCOHOLISM AND SCHIZOPHRENIA--EFFECTS OF CLOZAPINE
    Alan Green; Fiscal Year: 1999
    ..Confirmation that CLOZ decreases alcohol use in this population would have important public health implications and could lead to a new use for CLOZ. ..
  2. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan Green; Fiscal Year: 2009
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  3. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan I Green; Fiscal Year: 2010
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  4. Clozapine, cannabis and first episode schizophrenia
    Alan Green; Fiscal Year: 2003
    ....
  5. Cannabis & Schizophrenia: fMRI Reward Circuit Biomaker
    Alan Green; Fiscal Year: 2005
    ..Finding new medications, safer than CLOZ, that may be able to limit cannabis use In patients with SCHIZ is thus of considerable public health relevance. ..
  6. Antipsychotics and Alcohol Drinking in Rodents
    Alan Green; Fiscal Year: 2005
    ..The long-term goal of our research is to create better treatments for alcoholism in patients with SCH (and possibly even in those without SCH). ..
  7. CANNABIS AND SCHIZOPHRENIA: CLOZAPINE VS RISPERIDONE
    Alan Green; Fiscal Year: 2005
    ..If the results of this study confirm the preliminary data, they could suggest a new use for CLOZ, one that could have important public health implications. ..
  8. ALCOHOLISM AND SCHIZOPHRENIA--EFFECTS OF CLOZAPINE
    Alan Green; Fiscal Year: 2001
    ....
  9. Deconstructing Clozapine: Toward Medication for Alcoholism in Schizophrenia
    Alan I Green; Fiscal Year: 2010
    ....